Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Vertex

The No. 1 Biotech Stock to Buy for 2023

Biotech stock Vertex Pharmaceuticals (VRTX) outperformed its industry peers, gaining more than 30% over the past year. The company reported solid performance in the CF business and across the company in the last quarter. Moreover, VRTX is committed to delivering a diversified pipeline of transformative medicines and therapies. Hence, this…

StockNews.com

3 Stocks to Buy With Rising Recession and Rate Risk

The stock market continues to be a challenging environment with rising rates a potent headwind. So far, the economy has been stable enough so that earnings growth has not contracted, but this is unlikely to persist the longer the Fed stays hawkish. This article discusses characteristics of stocks that are…

StockNews.com

3 Stocks to Ride the Bear Market Rally

Stocks could be embarking on another bear market rally despite a plethora of challenges. One factor is we are entering a seasonally bullish period of the year. Another is the bullish technical setup following the undercut and recovery of the mid-June lows. 3 stocks that investors should consider buying to…

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

This Biotech Breakout Star is Our Growth Stock of the Week

Vertex Pharmaceuticals (VRTX) is a high-quality biotech stock that is quite cheap with impressive growth prospects. Read on to find out why it’s our growth stock of the week….

StockNews.com

3 Stocks to Buy With Rising Recession Risk, Increasing Geopolitical Tensions

Despite the bear market rally, the market is facing serious risks due to rising recession risk and increasing geopolitical tensions. Here are 3 defensive picks to help investors outperform in this tricky environment: Lockheed Martin (LMT), Vertex Pharmaceuticals (VRTX), and Elevance Health (ELVH).

StockNews.com

Daily Biotech Pulse: VistaGen's Anxiety Study Fails, Silverback To Merge With Firm Developing EpiPen Alternative, Setback For Liminal's Lead Asset

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

CRISPR, 10 Years On: Learning to Rewrite the Code of Life

Ten years ago this week, Jennifer Doudna and her colleagues published the results of a test-tube experiment on bacterial genes. When the study came out in the journal Science on June 28, 2012, it did not make headline news. In fact, over the next few weeks, it did not make…

Asharq Al-Awsat

Read news from The Economist, FT, and more,
with one subscription

4 "Strong Buy" Biotech Stocks to Add to Your Watchlist

As the Biotech industry’s role in finding cures for chronic diseases and critical conditions is expected to keep attracting investors’ attention, it could be wise to scoop up shares of the fundamentally-strong biotech companies Vertex Pharmaceuticals (VRTX), United Therapeutics (UTHR), Amgen (AMGN), and Sino Biopharmaceutical (SBHMY) because of their solid…

StockNews.com

VRTX is the Growth Stock of the Week

The market is in a tough place with stubbornly high inflation, a hawkish Fed, and a slowing economy. These conditions are tough for most stocks, but pharmaceuticals are an exception. One of the top companies in the space is Vertex Pharmaceuticals (VRTX). Read on to find out why it's our…

StockNews.com

Looking Into Vertex's Return On Capital Employed

According to data from Benzinga Pro, during Q1, Vertex's (NASDAQ:VERX) reported sales totaled $114.98 million. Despite a 46.73% increase in earnings, the company posted a loss of $334.00 thousand.

Benzinga

Irish parents ‘breaking down and crying’ as children denied life changing Cystic Fibrosis medication

Sarah O’Keeffe found out that her son would not be getting the medication that would improve his life

Dublin Live

Thousands sign petition demanding 35 kids with Cystic Fibrosis be given life-saving drug Kaftrio

'The lives of our children are at stake here, and we need to have this drug'

Irish Mirror

What 4 Analyst Ratings Have To Say About Vertex

Analysts have provided the following ratings for Vertex (NASDAQ:VERX) within the last quarter:

Benzinga

Mum of boy with rare life-threatening illness devastated as miracle drug to give child a normal life pulled

"The lives of our children are being put at risk because of a financial dispute"

Irish Mirror

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

2 Recession Stocks to Buy Right Now

Multi-decade-high inflation and aggressive Fed rate increases might push the economy into a recession. So, investors looking to mitigate a market downturn should invest in Dollar Tree (DLTR) and Vertex Pharmaceuticals (VRTX), as they could deliver stable returns because their businesses enjoy a near-inelastic demand.

Benzinga

Vertex Energy Clocks 61% Top-Line Growth In Q1

Vertex Energy Inc (NASDAQ:VTNR) reported first-quarter revenue growth of 60.6% year-over-year to $40.22 million, missing the consensus of $51.69 million. EPS loss was $(0.08) compared to $0.01 a year ago. The gross margin contracted by 466 bps to 3.8%. Vertex's operating loss increased to $(7.27) million from $(0.76) million a year ago.…

Benzinga

Recap: Vertex Q1 Earnings

Vertex (NASDAQ:VERX) reported its Q1 earnings results on Tuesday, May 10, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Benzinga

Why Vertex Pharmaceuticals Shares Are Falling

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) shares are trading lower by 3.42% to $263.88 during Monday’s pre-market session after the company announced VX-880 Phase 1/2 has been placed on clinical hold by the FDA due to “a determination that there is insufficient information to support do

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

This Obscure Stock Has Outperformed Tech And EV Giants

Vertex Energy Inc (NASDAQ: VTNR) has an average trading volume of over 2 million, so it is no slouch of a stock in terms of interest.

Benzinga

Vertex Touts Positive Data From Mid-Stage Study Of Its Non-Opioid Pain Drug

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) released positive results from two Phase 2 post-operative trials for its non-opioid program, VX-548. One trial looked at patients who had just received a bunionectomy (Correcting the deformity of toes & foot), the other in patients who received abdominoplasty (tummy tuck). Vertex said that within 48 hours of surgery,…

Newcastle Herald

Well played: Cause for celebration as cystic fibrosis drug added to the PBS

Without PBS subsidy, around 1,900 Australians would be up for more than $250,000 a year to access the CF drug.

Benzinga

What's Going On With Vertex Energy Shares Today?

Vertex Energy Inc (NASDAQ: VTNR) is trading higher on above-average volume Thursday as oil prices gain following the collapse of Russia-Ukraine ceasefire talks.

Benzinga

Vertex Clocks 12% Revenue Growth In Q4 Backed By ARR, NRR Momentum; Issues FY22 Guidance Above Consensus

Vertex Inc (NASDAQ:VERX) reported fourth-quarter FY21 revenue growth of 12.2% year-on-year to $111.7 million, beating the consensus of $109.2 million. Software subscription revenues rose 11.1% Y/Y to $93.3 million, and Cloud revenues increased 38.9% Y/Y to $34.7 million. Drivers: Annual Recurring Revenue rose 17% Y/Y to $370.2 million. The Average Annual Revenue per customer…

Benzinga

Vertex: Q4 Earnings Insights

Vertex (NASDAQ:VERX) reported its Q4 earnings results on Wednesday, March 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Benzinga

Vertex Energy Stock Skyrockets After Q4 Results; Expects To Close Mobile Refinery Deal As Planned

Vertex Energy Inc (NASDAQ:VTNR) reported fourth-quarter revenue growth of 82.5% year-over-year to $31.79 million, beating the consensus of $29.37 million. Q4 Adjusted net income recovered to $4.64 million from a loss of $(2.74) million in 4Q20. The gross margin declined by 130 bps to 1%. The company reported an operating loss of $(7.46)…

1 2 3 4 5

People

Mangeet Kaur BounsMangeet

Jaimini DesaiJaimini Desai

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.